nach oben

Erschienen in:

01.09.2017 | Cerebrovascular Disorders (DG Jamieson, Section Editor)

CADASIL: Treatment and Management Options

verfasst von: Anna Bersano, MD, PhD, Gloria Bedini, PhD, Joshua Oskam, MD, Caterina Mariotti, MD, Franco Taroni, MD, Silvia Baratta, PhD, Eugenio Agostino Parati, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Opinion statement

CADASIL is a life-threatening and disabling disease. Despite the progress achieved so far, no therapies able to limit the disease progression have been found and only empiric treatments can be employed to relieve the main disease symptoms. Further in vivo studies as well as data aggregation and multi-centre controlled clinical trials are needed to confirm the emerging findings in order to identify evidence-based therapies for CADASIL.

Ducros A, Nagy T, Alamowitch S, Nibbio A, Joutel A, Vahedi K, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval. Am J Hum Genet. 1996;58:171–81.PubMedPubMedCentral

Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8:643–53.CrossRefPubMed

Sourander P, Wålinder J. Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol. 1977;39:247–54.CrossRefPubMed

Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann N Y Acad Sci. 1997;826:213–7.CrossRefPubMed

Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science. 1995;268:225–32.CrossRefPubMed

Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731.CrossRefPubMed

Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127:2533–9.CrossRefPubMed

del Río-Espínola A, Mendióroz M, Domingues-Montanari S, Pozo-Rosich P, Solé E, Fernández-Morales J, et al. CADASIL management or what to do when there is little one can do. Expert Rev Neurother. 2009;9:197–210.CrossRefPubMed

Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke. 1999;30:1230–3.CrossRefPubMed

10.

Bousser M, Tournier-Lasserve E. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: from stroke to vessel wall physiology. J Neurol Neurosurg Psychiatry. 2001;70:285–7S.CrossRefPubMedPubMedCentral

11.

Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127:2031–8.CrossRefPubMed

12.

Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010;41:630–4.CrossRefPubMed

13.

Dichgans M. Cognition in CADASIL. Stroke. 2009;40:S45–7.CrossRefPubMed

14.

Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet. 1995;346:934–9.CrossRefPubMed

15.

Valenti R, Poggesi A, Pescini F, Inzitari D, Pantoni L. Psychiatric disturbances in CADASIL: a brief review. Acta Neurol Scand. 2008;118:291–5.CrossRefPubMed

16.

Choi JC, Kang SY, Kang JH, Park JK. Intracerebral hemorrhages in CADASIL. Neurology. 2006;67:2042–4.CrossRefPubMed

17.

Ragno M, Berbellini A, Cacchiò G, Manca A, Di Marzio F, Pianese L, et al. Parkinsonism is a late, not rare, feature of CADASIL: a study on Italian patients carrying the R1006C mutation. Stroke. 2013;44:1147–9.CrossRefPubMed

18.

Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH, et al. Diagnostic strategies in CADASIL. Neurology. 2002;59:1134–8.CrossRefPubMed

19.

• Zhu S, Nahas SJ. CADASIL: imaging characteristics and clinical correlation. Curr Pain Headache Rep. 2016;20:57. The study outlines the most important clinical and neuroimaging features of CADASIL confirming that subcortical ischemic changes, which occur early in CADASIL and typically progress to involve the anterior temporal poles, may differentiate CADASIL patients from other causes of small vessel ischemic diseaseCrossRefPubMed

20.

O’Sullivan M, Jarosz JM, Martin RJ, Deasy N, Powell JF, Markus HS. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology. 2001;56:628–34.CrossRefPubMed

21.

Lesnik Oberstein SA, van den Boom R, van Buchem MA, van Houwelingen HC, Bakker E, Vollebregt E, et al. Dutch CADASIL research group. Cerebral microbleeds in CADASIL. Neurology. 2001;57:1066–70.CrossRefPubMed

22.

Joshi S, Yau W, Kermode A. CADASIL mimicking multiple sclerosis: the importance of clinical and MRI red flags. J Clin Neurosci. 2017;35:75–7.CrossRefPubMed

23.

• Pantoni L, Pescini F, Nannucci S, Sarti C, Bianchi S, Dotti MT, et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology. 2010;74:57–63. The authors did not find any clinical or neuroimaging findings that were pathognomonic for CADASIL, emphasizing that there are many patients with a CADASIL like phenotype, despite negative genetic testingCrossRefPubMed

24.

He D, Chen D, Li X, Hu Z, Yu Z, Wang W, et al. The comparisons of phenotype and genotype between CADASIL and CADASIL-like patients and population-specific evaluation of CADASIL scale in China. J Headache Pain. 2016;17:55.CrossRefPubMedPubMedCentral

25.

Auer DP, Pütz B, Gössl C, Elbel G, Gasser T, Dichgans M. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology. 2001;218:443–51.CrossRefPubMed

26.

•• Bersano A, Markus HS, Quaglini S, Arbustini E, Lanfranconi S, Micieli G, et al., Lombardia GENS Group*. Clinical pregenetic screening for stroke monogenic diseases: results from Lombardia GENS Registry. Stroke. 2016;47:1702–9. The authors underline the need of clinical criteria for CADASIL suspicion. By applying standardized algorithm they identified 7% of patients with monogenic disease highlighting the role of familial history in the clinical suspicion of monogenic disease and specifically CADASILCrossRefPubMed

27.

Morroni M, Marzioni D, Ragno M, Di Bella P, Cartechini E, Pianese L, et al. Role of electron microscopy in the diagnosis of cadasil syndrome: a study of 32 patients. PLoS One. 2013;8:e65482.CrossRefPubMedPubMedCentral

28.

Tikka S, Mykkanen K, Ruchoux MM, Bergholm R, et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain. 2009;132:933–9.CrossRefPubMedPubMedCentral

29.

Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol. 2005;62:1091–4.CrossRefPubMed

30.

Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350:1511–5.CrossRefPubMed

31.

Bersano A, Ranieri M, Ciammola A, Cinnante C, Lanfranconi S, Dotti MT, et al. Considerations on a mutation in the NOTCH3 gene sparing a cysteine residue: a rare polymorphism rather than a CADASIL variant. Funct Neurol. 2012;27:247–52.PubMed

32.

Rutten JW, Haan J, Terwindt GM, van Duinen SG, Boon EM, Lesnik Oberstein SA. Interpretation of NOTCH3 mutations in the diagnosis of CADASIL. Expert Rev Mol Diagn. 2014;14:593–603.CrossRefPubMed

33.

• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6. In this review Notch signals is reported to control how cells respond to intrinsic or extrinsic developmental cues that are necessary to unfold specific developmental programs. It is also explained how Notch activity affects differentiation, proliferation, and apoptotic programs, providing a general developmental tool to influence organ formation and morphogenesisCrossRefPubMed

34.

• Joutel A, Corpechot C, Ducros A, Vahedi K, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 383:1996, 707–710. This research article first reported that specific mutations in the NOTCH3 gene cause serious disruption of the gene, indicating that Notch3 could be the defective protein in CADASIL patients

35.

Joutel A. Pathogenesis of CADASIL: transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature. BioEssays. 2011;33:73–80.CrossRefPubMed

36.

Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am J Hum Genet. 2004;74:338–47.CrossRefPubMedPubMedCentral

37.

Dotti MT, Federico A, Mazzei R, Bianchi S, Scali O, Conforti FL, et al. The spectrum of Notch3 mutations in 28 Italian CADASIL families. J Neurol Neurosurg Psychiatry. 2005;76:736–8.CrossRefPubMedPubMedCentral

38.

•• Bianchi S, Zicari E, Carluccio A, Di Donato I, Pescini F, Nannucci S, et al. CADASIL in central Italy: a retrospective clinical and genetic study in 229 patients. J Neurol. 2015;262:134–41. This is the most extensive study on CADASIL in Italy. This study enlarges the number of pathogenic NOTCH3 gene mutations and highlights the heterogeneous mutational spectrum observed suggesting that full sequencing of exons 2–24 is mandatory for CADASIL screening in ItalyCrossRefPubMed

39.

Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 2007;6:149–61.CrossRefPubMed

40.

Duering M, Karpinska A, Rosner S, Hopfner F, Zechmeister M, Peters N, et al. Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. Hum Mol Genet. 2011 Aug 15;20(16):3256–65.CrossRefPubMed

41.

Smith RA, Curtain R, Ovcaric M, Tajouri L, Macmillan J, Griffiths L. Investigation of the NOTCH3 and TNFSF7 genes on C19p13 as candidates for migraine. Open Neurol J. 2008;2:1–7.CrossRefPubMedPubMedCentral

42.

• Wollenweber FA, Hanecker P, Bayer-Karpinska A, Malik R, Bäzner H, Moreton F, et al. Cysteine-sparing CADASIL mutations in NOTCH3 show proaggregatory properties in vitro. Stroke. 2015;46:786–92. This paper discusses and provides recommendations for the interpretation of NOTCH3 gene mutations in the diagnosis of CADASILCrossRefPubMed

43.

Joutel A, Monet-Leprêtre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest. 2010;120:433–45.CrossRefPubMedPubMedCentral

44.

Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000;105:597–605.CrossRefPubMedPubMedCentral

45.

Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001;358:2049–51.CrossRefPubMed

46.

Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3 ectodomain is a major component of granular osmiophilic material (GOM) in CADASIL. Acta Neuropathol. 2006;112:333–9.CrossRefPubMed

47.

• Ghosh M, Balbi M, Hellal F, Dichgans M, Lindauer U, Plesnila N. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Ann Neurol. 2015;78:887–900. In this research article pericytes are reported to be the first cells affected by Notch3 aggregation in CADASIL mice, causing opening of the blood brain barrier and microvascular dysfunction. Therefore, protecting pericytes may represent a novel therapeutic strategy for vascular dementiaCrossRefPubMed

48.

Monet-Leprêtre M, Haddad I, Baron-Menguy C, Fouillot-Panchal M, Riani M, Domenga-Denier V, et al. Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. Brain. 2013;136:1830–45.CrossRefPubMedPubMedCentral

49.

Morrow D, Guha S, Sweeney C, Birney Y, Walshe T, O’Brien C, et al. Notch and vascular smooth muscle cell phenotype. Circ Res. 2008;103:1370–82.CrossRefPubMed

50.

Krebs LT, Xue Y, Norton CR, Sundberg JP, Beatus P, Lendahl U, et al. Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with a Notch1 mutation. Genesis. 2003 Nov;37(3):139–43.

51.

Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 2004;18:2730–5.CrossRefPubMedPubMedCentral

52.

Belin de Chantemèle EJ, Retailleau K, Pinaud F, Vessières E, Bocquet A, Guihot AL, et al. Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vasc Biol. 2008;28:2216–24.CrossRefPubMed

53.

Rutten JW, Klever RR, Hegeman IM, Poole DS, Dauwerse HG, Broos LA, et al. The NOTCH3 score: a pre-clinical CADASIL biomarker in a novel human genomic NOTCH3 transgenic mouse model with early progressive vascular NOTCH3 accumulation. Acta Neuropathol Commun. 2015;3:89.CrossRefPubMedPubMedCentral

54.

•• Di Donato I, Bianchi S, De Stefano N, Dchgans M, Dotti MT, Duering M, et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Med. 15(1):41. The paper is an important updated review on clinical, neuroimaging, neuropathological, genetic, and therapeutic aspects based on literature and on the personal experience of the authors, with a wide expertise in CADASIL research and care

55.

Khan MT, Murray A, Smith M. Successful use of intravenous tissue plasminogen activator as treatment for a patient with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: acase report and review of literature. J Stroke Cerebrovasc Dis. 2016;25:e53–7.

56.

Dichgans M, Petersen D. Angiographic complications in CADASIL. Lancet. 1997;349:776–7.CrossRefPubMed

57.

Holtmannspötter M, Peters N, Opherk C, Martin D, Herzog J, Brückmann H, et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke. 2005;36:2559–65.CrossRefPubMed

58.

Viswanathan A, Guichard JP, Gschwendtner A, Buffon F, Cumurcuic R, Boutron C, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain. 2006;129:2375–8.CrossRefPubMed

59.

Peters N, Holtmannspötter M, Opherk C, Gschwendtner A, Herzog J, Sämann P, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. Neurology. 2006;66:1517–22.CrossRefPubMed

60.

Guo Z, Qiu C, Viitanen M, Fastbom J, Winblad B, Fratiglioni L. Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. J Alzheimers Dis. 2001;3:585–91.CrossRefPubMed

61.

Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61:1667–72.CrossRefPubMed

62.

Rufa A, Dotti MT, Franchi M, Stromillo ML, Cevenini G, Bianchi S, et al. Systemic blood pressure profile in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2005;36:2554–8.CrossRefPubMed

63.

Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224–32.CrossRefPubMed

64.

Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346:476–83.CrossRefPubMed

65.

Hassan A, Hunt BJ, O’Sullivan M, Bell R, D’Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127:212–9.CrossRefPubMed

66.

Flemming KD, Nguyen TT, Abu-Lebdeh HS, Parisi JE, Wiebers DO, Sicks JD, et al. Hyperhomocysteinemia in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Mayo Clin Proc. 2001 Dec;76:1213–8.

67.

Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015;1:CD006612.PubMed

68.

Park JH, Saposnik G, Ovbiagele B, Markovic D, Towfighi A. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: a meta-analysis. Int J Stroke. 2016;11:206–11.CrossRefPubMed

69.

Lian L, Li D, Xue Z, Liang Q, Xu F, Kang H, et al. Spontaneous intracerebral hemorrhage in CADASIL. J Headache Pain. 2013;14:98.CrossRefPubMedPubMedCentral

70.

Rinnoci V, Nannucci S, Valenti R, Donnini I, Bianchi S, Pescini F, et al. Cerebral hemorrhages in CADASIL: report of four cases and a brief review. J Neurol Sci. 2013;330:45–51.CrossRefPubMed

71.

van den Boom R, Lesnik Oberstein SA, Spilt A, Behloul F, Ferrari MD, Haan J, et al. Cerebral hemodynamics and white matter hyperintensities in CADASIL. J Cereb Blood Flow Metab. 2003;23:599–604.CrossRefPubMed

72.

Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke. 2000;31:1904–12.CrossRefPubMed

73.

Tuominen S, Miao Q, Kurki T, Tuisku S, Pöyhönen M, Kalimo H, et al. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke. 2004;35:1063–7.CrossRefPubMed

74.

Pfefferkorn T, von Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced cerebrovascular CO(2) reactivity in CADASIL: a transcranial Doppler sonography study. Stroke. 2001;32:17–21.CrossRefPubMed

75.

Campolo J, De Maria R, Frontali M, Taroni F, Inzitari D, Federico A, et al. Impaired vasoreactivity in mildly disabled CADASIL patients. J Neurol Neurosurg Psychiatry. 2012;8:268–74.CrossRef

76.

Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. J Neurol Sci. 2007;260:100–5.CrossRefPubMed

77.

De Maria R, Campolo J, Frontali M, Taroni F, Federico A, Inzitari D, et al. Effects of sapropterin on endothelium-dependent vasodilation in patients with CADASIL: a randomized controlled trial. Stroke. 2014 Oct;45:2959–66.

78.

Huang L, Yang Q, Zhang L, Chen X, Huang Q, Wang H. Acetazolamide improves cerebral hemodynamics in CADASIL. J Neurol Sci. 2010;292:77–80.CrossRefPubMed

79.

Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, et al. Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clin Neuropharmacol. 2009;32:113–6.CrossRefPubMed

80.

Goldstein J, Hagen M, Gold M. Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine. Cephalalgia. 2014;34:1070–8.CrossRefPubMed

81.

Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001 Nov 17;358(9294):1668–75.

82.

Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M, Henry P, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123:9–18.CrossRefPubMed

83.

Martikainen MH, Roine S. Rapid improvement of a complex migrainous episode with sodium valproate in a patient with CADASIL. J Headache Pain. 2012;13:95–7.CrossRefPubMed

84.

Finocchi C, Villani V, Casucci G. Therapeutic strategies in migraine patients with mood and anxiety disorders: clinical evidence. Neurol Sci. 2010;31(Suppl 1):S95–8.CrossRefPubMed

85.

Donnini I, Nannucci S, Valenti R, Pescini F, Bianchi S, Inzitari D, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain. 2012;13:299–302.CrossRefPubMedPubMedCentral

86.

Lippi G, Mattiuzzi C, Meschi T, Cervellin G, Borghi L. Homocysteine and migraine. A narrative review. Clin Chim Acta. 2014;433:5–11.CrossRefPubMed

87.

Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal deficits in CADASIL. Stroke. 2007;38:188–91.CrossRefPubMed

88.

Manganelli F, Ragno M, Cacchiò G, Iodice V, Trojano L, Silvaggio F, et al. Motor cortex cholinergic dysfunction in CADASIL: a transcranial magnetic demonstration. Clin Neurophysiol. 2008;119:351–5.CrossRefPubMed

89.

Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310–8.CrossRefPubMed

90.

Schneider LS. Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008;7:287–9.CrossRefPubMed

91.

Posada IJ, Ferrero M, Lopez-Valdes E, Goni-Imizcoz M. Galantamine therapy in dementia associated with CADASIL. Rev Neurol. 2008;47:299–300.PubMed

92.

McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006:CD003154.

93.

Ho RC, Cheung MW, Fu E, Win HH, Zaw MH, Ng A, et al. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry. 2011;19:607–17.CrossRefPubMed

94.

Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJ, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100:657–66.CrossRefPubMedPubMedCentral

95.

Andersson ER, Lendahl U. Therapeutic modulation of Notch signaling—are we there yet? Nat Rev Drug Discov. 2014;13:357–78.CrossRefPubMed

96.

Shin D, Oh YH, Eom CS, Park SM. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol. 2014;261:686–95.CrossRefPubMed

97.

Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012 Nov 14;11:CD009286.

98.

Park S, Park B, Koh MK, Joo YH. Case report: bipolar disorder as the first manifestation of CADASIL. BMC Psychiatry. 2014;14:175.CrossRefPubMedPubMedCentral

99.

Ho CS, Mondry A. CADASIL presenting as schizophreniform organic psychosis. Gen Hosp Psychiatry. 2015;37:273.e11–3.CrossRef

100.

• Tikka S, Ng YP, Di Maio G, Mykkänen K, Siitonen M, Lepikhova T, et al. CADASIL mutations and shRNA silencing of NOTCH3 affect actin organization in cultured vascular smooth muscle cells. J Cereb Blood Flow Metab. 2012;32:2171–80. The results of the present study support the view that VSMCs in different vascular beds are dissimilar and consequently the pathogenic effects of mutated NOTCH3 gene are also dissimilar in different arteriesCrossRefPubMedPubMedCentral

101.

• Rutten JW, Dauwerse HG, Peters DJ, Goldfarb A, Venselaar H, Haffner C, et al. Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. Brain. 2016;139:1123–35. This research article examined the technical feasibility of targeted NOTCH3 exon skipping, by designing antisense oligonucleotides targeting exons 2–3, 4–5 and 6, which together harbor the majority of distinct CADASIL-causing mutations. This novel application of exon skipping is a first step towards the development of a rational therapeutic approach applicable to up to 94% of CADASIL-causing mutationsCrossRefPubMed

102.

Gong L, Liu X-Y, Fang M. Recent progress on small vessel disease with cognitive impairment. Int J Clin Exp Med. 2015;8:7701–9.PubMedPubMedCentral

103.

MacLeod R, Tibben A, Frontali M, Evers-Kiebooms G, Jones A, Martinez-Descales A, et al. Editorial Committee and Working Group ‘Genetic Testing Counselling’ of the European Huntington Disease Network. Recommendations for the predictive genetic test in Huntington’s disease. Clin Genet. 2013;83:221–31.CrossRefPubMed

104.

Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L, et al. CADASIL and CARASIL. Brain Pathol. 201(24):525–44.

105.

Peters N, Herzog J, Opherk C, Dichgans M. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke. 2004;35:1603–8.CrossRefPubMed

106.

• Chabriat H, Hervé D, Duering M, Godin O, Jouvent E, Opherk C, et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: prospective cohort study. Stroke. 2016;47:4–11. This large prospective study on NOTCH3 gene mutation carriers reported that clinical status (particularly gait disturbance,) as well as the number of lacunes and brain volume, are a major independent predictor of clinical worseningCrossRefPubMed

Titel: CADASIL: Treatment and Management Options
verfasst von: Anna Bersano, MD, PhD
Gloria Bedini, PhD
Joshua Oskam, MD
Caterina Mariotti, MD
Franco Taroni, MD
Silvia Baratta, PhD
Eugenio Agostino Parati, MD
Publikationsdatum: 01.09.2017
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 9/2017
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-017-0468-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen